Comparative Study
Formulation of three nitrosoureas for intravenous use
- PMID: 4201309
Item in Clipboard
Comparative Study
Formulation of three nitrosoureas for intravenous use
Cancer Chemother Rep 3.
1973 May.
No abstract available
Similar articles
-
Nitrosoureas in central nervous system tumors.Cancer Chemother Rep 3. 1973 May;4(3):21-6. Cancer Chemother Rep 3. 1973. PMID: 4584033 Review. No abstract available.
-
Current status of new agents.Cancer Chemother Rep 3. 1972 May;3(1):33-47. Cancer Chemother Rep 3. 1972. PMID: 4116662 Review. No abstract available.
-
3-(Tetraacetyl glucopyranos-2-yl)-1-(2-chloroethyl)-1-nitrosourea, an antitumor agent with modified bone marrow toxicity.Cancer Res. 1973 Sep;33(9):2005-9. Cancer Res. 1973. PMID: 4353476 No abstract available.
-
1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review.Adv Cancer Res. 1972;16:273-332. doi: 10.1016/s0065-230x(08)60343-7. Adv Cancer Res. 1972. PMID: 4563045 Review. No abstract available.
-
Interrelationships of some chemical, physicochemical, and biological activities of several 1-(2-haloethyl)-1-nitrosoureas.Cancer Res. 1974 Jan;34(1):194-200. Cancer Res. 1974. PMID: 4809457 No abstract available.
Cited by
-
Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents.Cancer Chemother Pharmacol. 1985;14(2):83-95. doi: 10.1007/BF00434343. Cancer Chemother Pharmacol. 1985. PMID: 3882257 Review.
-
Distribution of Bratton-Marshall-positive material in mice following intravenous injections of nitrosoureas.Cancer Chemother Pharmacol. 1980;4(4):243-8. doi: 10.1007/BF00255268. Cancer Chemother Pharmacol. 1980. PMID: 7438326